FDA OKs Benralizumab for Asthma in Children as Young as 6 Years

Marketed as Fasenra, the medication first was approved in 2017 for patients aged 12 years or older. The drug is approved as a maintenance add-on for patients with severe eosinophilic asthma. that showed that the drug functions in the same way with younger children and their adolescent peers. The safety and tolerability were also consistent with the known profile of the medicine, the company said.

For children who weigh ≥ 35 kg, the recommended dose is 30 mg. For patients aged 6-11 years who weigh < 35 kg, a new 10-mg dose will be available, according to the announcement. The drug, a monoclonal antibody that depletes eosinophils by binding to interleukin 5 receptor alpha on eosinophils, is administered by subcutaneous injection every 4 weeks for the first three doses and then every 8 weeks.

Benralizumab should not be used to treat acute asthma symptoms. Hypersensitivity reasons have occurred after administration of the drug. The most common adverse reactions includeAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

Source: Healthcare Press (healthcarepress.net)

Asthmatic Severe Asthma Uncontrolled Asthma Childhood Asthma Severe Allergic Asthma Uncontrolled Allergic Asthma Children Child Childhood Pediatrics Kids Otolaryngology ENT Specialty Head And Neck Surgery ENT Speciality Eosinophils Eosinophil Granulocytes Adolescent Medicine Teens Teenage Teenager Adolescent Health Adolescents Adolescent U.S. Food And Drug Administration

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA OKs First CAR T-cell Trial for Children With LupusThe trial is expected to begin this summer and will enroll 12 individuals under age 18 years.
Source: Medscape - 🏆 386. / 55 Read more »

FDA OKs First Gene Therapy for Metachromatic LeukodystrophyAtidarsagene autotemcel (Lenmeldy) is approved for presymptomatic late infantile, presymptomatic early juvenile, or early symptomatic early juvenile MLD.
Source: Medscape - 🏆 386. / 55 Read more »

FDA OKs Givinostat for Duchenne Muscular DystrophyGivinostat (Duvyzat), a histone deacetylase inhibitor, is the first nonsteroidal drug approved to treat patients aged 6 years or older with all genetic variants of DMD.
Source: Medscape - 🏆 386. / 55 Read more »

FDA OKs New Treatment to Prevent COVID in High-Risk PeopleA new antibody treatment has been approved to help prevent COVID-19, and it will be available in a matter of days for many of the estimated 3 in every 100 people in the U.S. who have compromised immune systems.
Source: WebMD - 🏆 709. / 51 Read more »

FDA OKs Sotatercept, First-in-Class Agent for Pulmonary Arterial HypertensionSotatercept with background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone in the STELLAR trial.
Source: Medscape - 🏆 386. / 55 Read more »